+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 90Years
All Genders
ID07513285

Oral Ibezapolstat ACX-362E for Treating Recurrent Clostridioides Difficile Infection in Adults With Multiple Recurrences

Led by Acurx Pharmaceuticals Inc. · Updated on 2026-10-16

20

Participants Needed

19

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of ibezapolstat, an oral drug, for treating recurrent Clostridioides difficile infection CDI in adults who have had three or more CDI episodes in the past year. This phase 2, open-label, single-arm study focuses on adults aged 18 to 90 years who have experienced multiple recurrent infections. The trial aims to assess how well ibezapolstat treats the infection and reduces the chances of it coming back. Participants will receive ibezapolstat 450 mg by mouth every 12 hours with food for 14 days, totaling 28 doses. After treatment, participants will be monitored through several follow-up periods including Day 16 for Clinical Cure, Day 42 for Sustained Clinical Cure, and up to Week 24 to observe recurrence rates and Extended Clinical Cure. The treatment and follow-up schedule is designed to evaluate the drugs effect over time on CDI recurrence and recovery. During the study, participants will undergo assessments for diarrhea resolution, stool tests for infection, and monitoring of their fecal microbiome changes from Day 1 through Week 24. Researchers will track safety, tolerability, and treatment response through clinical visits and laboratory evaluations. The total participation duration includes treatment and follow-up assessments up to approximately 24 weeks to fully understand the drugs impact on recurrent CDI.

CONDITIONS

Brief Title

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

Research Team

D

Dee Rodriguez

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here